# Why Cheaper Humira Alternatives Face Resistance

Written by The Life Science Feed Editorial Team · Published 1 June 2026 · Edited by James Carter

**KEY TAKEAWAYS**

- Biosimilars are approved to stringent regulatory standards - approved biosimilars are not inferior products
- NOR-SWITCH and multiple subsequent studies consistently show switching from reference biologic to biosimilar is safe and maintains remission
- The nocebo effect is real - patient counselling about biosimilar equivalence is a clinical responsibility that directly affects discontinuation rates
- NHS England biosimilar adoption reduced adalimumab spend by more than 50% while treating more patients; this dividend funded access to newer on-patent biologics

## EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

## REFERENCES

1. 1. Jorgensen KK et al. NOR-SWITCH. Lancet. 2017;389:2304-2316
2. 2. NHS England. Biosimilar medicines: a guide for primary care. 2022
3. 3. Kay J et al. Ann Rheum Dis. 2018;77:1658-1665
4. 4. Smolen JS et al. EULAR RA Recommendations 2023. Ann Rheum Dis. 2023

## LICENCE & RIGHTS



## MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

## FOLLOW THE LIFE SCIENCE FEED

**Instagram** @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com